Eckhard Brueggemann - STADA Arzneimittel Insider

STDAF -- USA Stock  

USD 96.10  0.00  0.00%

  Executive
Dr. Eckhard Brueggemann was Member of the Supervisory Board of STADA Arzneimittel AG from August 24 2009 August 26 2016. From February 5 2001 to August 24 2009 he occupied the position of Chairman of the Supervisory Board at the Company. Before that he served as Member of the Supervisory Board at STADA Arzneimittel AG from 1997. He started a medical practice in Herne Germany in 1972. From 1983 to 1993 he was Chairman of the German Association of General Practitioners. Since 1993 he was a Board Member of the Federal Association of German Family Doctors. In 1997 he was elected to the Supervisory Board of STADA Arzneimittel AG. He completed his medical studies in Marburg and Essen Germany and Innsbruck Austria and is a specialist in general medicine.
Age: 75  Executive Since 2009  Ph.D    
49 6101 603 0  http://www.stada.de

Management Efficiency

The company has return on total asset (ROA) of 6.33 % which means that it generated profit of $6.33 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 14.86 % meaning that it generated $14.86 on every $100 dollars invested by stockholders.
The company has accumulated 1.65 B in total debt with debt to equity ratio (D/E) of 123.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. STADA Arzneimittel Aktiengesellschaft has Current Ratio of 1.22 suggesting that it may have difficulties to pay its financial obligations in time and when they become due.

Similar Executives

Showing few of many executives

EXECUTIVE Since

Constantin FestMerck Kommanditgesellschaft auf
N/A
Kedar UpadhyeDr Reddys Laboratories Limited
N/A
Edeltraud GlaenzerMerck Kommanditgesellschaft auf
N/A
Tobias ThelenMerck Kommanditgesellschaft auf
2014
Matsuo KikuchiMitsubishi Tanabe Pharma Corpor
N/A
Kai BeckmannMerck Kommanditgesellschaft auf
2017
Isabel PaoliMerck Kommanditgesellschaft auf
2016
Peter SpeirsHikma Pharmaceuticals PLC
2012
Riaan VersterAspen Pharmacare Holdings Limit
2013
Nilda RiveraAurora Cannabis
2017
Saunak SavlaDr Reddys Laboratories Limited
2016
Andrew PlumpTakeda Pharmaceutical Company L
2015
Minoru MuramatsuMitsubishi Tanabe Pharma Corpor
N/A
Shigeru DosekiMitsubishi Tanabe Pharma Corpor
2017
Theo SiegertMerck Kommanditgesellschaft auf
2006
Gregor SchulzMerck Kommanditgesellschaft auf
2014
Gabriele EismannMerck Kommanditgesellschaft auf
2014
Hussein ArkhaghaHikma Pharmaceuticals PLC
2013
Allan CleirenAurora Cannabis
2017
Cameron BattleyAurora Cannabis
2018
Anke SchenkelMerck Kommanditgesellschaft auf
2017

Entity Summary

STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of pharmaceutical products for the health care and pharmaceutical markets worldwide. STADA Arzneimittel Aktiengesellschaft is a subsidiary of Nidda Healthcare Holding GmbH. STADA Arzneimittel operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. It employs 10232 people.STADA Arzneimittel Aktiengesellschaft (STDAF) is traded on OTC Market in USA. It is located in Stadastrasse 2-18 and employs 10,232 people.

STADA Arzneimittel Leadership Team

Carl Oetker, Member of the Supervisory Board
JanNicolas Garbe, Member of the Supervisory Board
Dieter Koch, Member of the Supervisory Board
Eckhard Brueggemann, Member of the Supervisory Board
Mark Keatley, CFO, Member of the Executive Board
Ralph Grobecker, Managing Director of OTC segment
Martin Abend, Chairman of the Supervisory Board
Matthias Wiedenfels, Chief Bus. Devel. and Central Services Officer and Member of Executive Board
Arnold Hertzsch, Member of the Supervisory Board
Halil Duru, Member of the Supervisory Board
Tina Mueller, Member of the Supervisory Board
Engelbert Willink, Chairman of the Executive Board, CEO
Barthold Piening, Chief Technical Operations Officer, Member of the Executive Board
Steffen Wagner, Member of the Management Board, Head of Europe
Helmut Kraft, CFO and Member of Executive Board
Ute Pantke, Member of the Supervisory Board
Carsten Cron, Member of the Management Board, Head Emerging Markets
Frank Seiler, IR Contact Officer
Hartmut Retzlaff, Chairman of The Executive Board
Bernhard Duettmann, CFO
Miguel Pagan, Member of the Executive Board
Claudio Albrecht, Chairman of the Executive Board, CEO
Michael Siefke, Member of the Supervisory Board
Leslie Iltgen, Vice President Investor Relations
Eric Cornut, Member of the Supervisory Board
Peter Goldschmidt, Chairman of the Executive Board
Robert Knerr, Member of the Management Board, Head of Business Development
Jens Steegers, Member of the Supervisory Board
Birgit Kudlek, Member of the Supervisory Board
Guenter Au, Chairman of the Supervisory Board
Constantin Meyer, Member of the Supervisory Board
Rolf Hoffmann, Member of the Supervisory Board
Markus Metzger, Director of Investor Relations
Benjamin Kunstler, Member of the Supervisory Board
Gunnar Riemann, Member of the Supervisory Board
Bruno Schick, Member of the Supervisory Board

Stock Performance Indicators

Did you try this?

Run Analyst Recommendations Now

   

Analyst Recommendations

Analyst recommendations and target price estimates broken down by several categories
All  Next Launch Analyst Recommendations
Currently Active Assets on Macroaxis
CRM   
Purchased a lot of shares of
few days ago
Traded for 156.0
CRM   
Purchased a lot of shares of
few days ago
Traded for 156.0
F   
Purchased over 300 shares of
few days ago
Traded for 9.81
C   
Purchased over 40 shares of
few days ago
Traded for 74.735
GM   
Purchased over 70 shares of
few days ago
Traded for 36.08
Also please take a look at World Market Map. Please also try Cryptocurrency Arbitrage module to find pairs of digital assets on multiple exchanges that are traded at a risk free arbitrage.
Search macroaxis.com